Africa & Middle East

The report highlights how a targeted, mechanism-based approach helped manage a rare and complex form of obesity that developed after severe brain injury in infancy.

The agreement was formalised during a signing ceremony held at ADCAN Pharma’s advanced manufacturing facility in Abu Dhabi, bringing together senior leadership from both organisations and key healthcare stakeholders.

The Department of Health has begun distributing the injectable through an initial network of 360 health facilities located in high-burden districts.

The hospital met all required standards set by the Saudi Patient Safety Center, reflecting strong compliance with structured safety protocols and system-wide quality controls across its clinical and operational departments.

Neurodiversity remains a central focus, particularly in identifying autism and ADHD in girls, women, and high-achieving adults who often mask symptoms for years before receiving support.

The project includes a specialised training academy designed to develop advanced skills in biotechnology, quality control, and vaccine production, ensuring a steady pipeline of qualified personnel to support long-term operations and sector growth.

The researchers designed the device to work seamlessly with existing medical imaging technologies, including ultrasound and CT scans.

The hospital introduced the programme as part of broader efforts to reduce the burden of airborne diseases through stronger community engagement and evidence-based interventions.

The facility will occupy approximately 3,000 square metres and will comprise a ground floor, five upper levels, and a rooftop, reaching a height of 27.75 metres.

Under the new agreement, EDE and Novo Nordisk will work together to enhance pharmaceutical supply chain security by increasing in-country value creation and expanding strategic partnerships that help maintain a steady supply of medicines.